# SOLIGENIX (SNGX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/SNGX
## Company Profile
- Ticker: SNGX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 0.3865 USD
- Market cap: 11100341.4912 USD
- Last updated: 2026-08-11
## Business Overview
### Rare-Disease Biopharmaceutical Company
Soligenix develops therapies for rare diseases with substantial unmet need. Its pipeline has included oncology, inflammatory-disease and biodefense programs.
### HyBryte
HyBryte is a synthetic hypericin photodynamic therapy developed for cutaneous T-cell lymphoma. Its confirmatory Phase 3 FLASH2 study was stopped for futility following an interim analysis, creating uncertainty around the program's path forward.
### Dusquetide
SGX945, or dusquetide, is an innate-defense regulator that has generated prior clinical data in Behçet's disease. Soligenix is evaluating strategic options, including whether to advance this program.
## Why The Stock Is Moving

As of Aug 11, 2026, SNGX closed up 2.38% at $0.3865. No new same-company headline was identified in the current news window.

## Recent News
- 2026-08-07 11:30 EST — [Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/SNGX/soligenix-announces-recent-updates-and-second-quarter-2026-financial-results-6b343331) — Source: SOLIGENIX
- 2026-06-08 11:30 EST — [Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine](https://biopharmsignal.com/news/SNGX/soligenix-applying-for-vaccine-development-funding-for-bundibugyo-ebola-vaccine-a724aab6) — Source: SOLIGENIX
- 2026-05-26 11:30 EST — [Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo](https://biopharmsignal.com/news/SNGX/suitability-of-vaccine-platform-for-bundibugyo-virus-cause-of-the-ebola-outbreak-in-congo) — Source: SOLIGENIX
- 2026-05-08 11:30 EST — [Soligenix Announces Recent Updates and First Quarter 2026 Financial Results](https://biopharmsignal.com/news/SNGX/soligenix-announces-recent-updates-and-first-quarter-2026-financial-results) — Source: SOLIGENIX
- 2026-04-28 11:30 EST — [Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma](https://biopharmsignal.com/news/SNGX/soligenix-announces-interim-results-from-the-phase-3-flash2-trial-evaluating-hybrytetm-in-treatment-of-cutaneous-t-cell-lymphoma) — Source: SOLIGENIX